Vertical transmission of multidrug-resistant Q151m human immunodeficiency virus type 1 strains

Pediatric Infectious Disease Journal

Volumn 27, Issue 3, 2008, Pages 278-280

  Henry, Mireille ^a,b   Thuret, Isabelle ^a   Solas, Caroline ^a   Genot, Sèverine ^b,c   Colson, Philippe ^a,b,d   Tamalet, Catherine ^a,b  

^a CHRU Timone   (France)

^b AIX MARSEILLE UNIVERSITY   (France)

^c HÔPITAL DE LA CONCEPTION   (France)

^d TIMONE HOSPITAL   (France)

Author keywords

Children; Drug resistance mutations; HIV 1; Q151M; Vertical transmission

Indexed keywords

ANTIRETROVIRUS AGENT; DIDANOSINE; INDINAVIR; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; VIRUS RNA; ZIDOVUDINE;

ADULT; ARTICLE; CASE REPORT; CESAREAN SECTION; CHILD; DISEASE TRANSMISSION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MONITORING; DRUG WITHDRAWAL; FEMALE; GENE MUTATION; GENOTYPE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INFANT; MOTHER; MULTIDRUG RESISTANCE; PATIENT COMPLIANCE; PREGNANCY; PRIORITY JOURNAL; REPEATED DRUG DOSE; STRAIN DIFFERENCE; TREATMENT FAILURE; TREATMENT OUTCOME; VERTICAL TRANSMISSION; VIRUS LOAD; VIRUS TRANSMISSION; AMINO ACID SUBSTITUTION; ANTIVIRAL RESISTANCE; DRUG EFFECT; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ISOLATION AND PURIFICATION; NEWBORN; VIROLOGY;

ADULT; AMINO ACID SUBSTITUTION; ANTI-RETROVIRAL AGENTS; DISEASE TRANSMISSION, VERTICAL; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; INFANT, NEWBORN; PREGNANCY;

EID: 44949112525     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e31815db4c6     Document Type: Article

References (15)

1. European Collaborative Study. Mother-to-child transmission of HIV infection in the era of highly active antiretroviral therapy. Clin Infect Dis. 2005;40:458-465.
2. Schmitz T, Kleinkauf N, Klempa B, Ringe H, Varnholt V, Grosch-Worner I. Transmission of human immunodeficiency virus type 1 nevirapine resistance mutation K103N from a treatment-naive mother to her child. Pediatr Infect Dis J. 2006;25:275-276.
3. Kijak GH, Avila MM, Salomon H. Mother-to-child transmission of drug-resistant HIV. Drug Resist Updat. 2001;4:29-37.
4. Henry M, Tourres C, Colson P, Ravaux I, Poizot-Martin I, Tamalet C. Coexistence of the K65R/L74V and/or K65R/T215Y mutations on the same HIV-1 genome. J Clin Virol. 2006;37:227-230.
5. Yeni P. Prise en charge des enfants et adolescents infectés par le VIH. In: Flammarion MS, ed. Prise en Charge Thérapeutique des Personnes Infectéle VIH. Recommandations du groupe d'experts; 2006:123-148.
6. Parker MM, Wade N, Lloyd RM Jr, et al. Prevalence of genotypic drug resistance among a cohort of HIV-infected newborns. J Acquir Immune Defic Syndr. 2003;32:292-297.
7. Karchava M, Pulver W, Smith L, et al. Prevalence of drug-resistance mutations and non-subtype B strains among HIV-infected infants from New York State. J Acquir Immune Defic Syndr. 2006;42:614-619.
8. Van Vaerenbergh K, Van Laethem K, Albert J, et al. Prevalence and characteristics of multinucleoside-resistant human immunodeficiency virus type 1 among European patients receiving combinations of nucleoside analogues. Antimicrob Agents Chemother. 2000;44:2109-2117.
9. Pasquier C, Cayrou C, Blancher A, et al. Molecular evidence for mother-to-child transmission of multiple variants by analysis of RNA and DNA sequences of human immunodeficiency virus type 1. J Virol. 1998;72:8493-8501.0
10. Delaugerre C, Morand-Joubert L, Chaix ML, et al. Persistence of multidrug-resistant HIV-1 without antiretroviral treatment 2 years after sexual transmission. Antivir Ther. 2004;9:415-421.1
11. Little S, Holte S, Routy JP, et al. Antiretroviral drug resistance among patients recently infected with HIV. N Engl J Med. 2002;347:385-394.2
12. Resino S, Bellon JM, Ramos JT, et al. Salvage lopinavir-ritonavir therapy in human immunodeficiency virus-infected children. Pediatr Infect Dis J. 2004;23:923-930.3
13. Chiappini E, Galli L, Tovo PA, et al.; Italian Register for HIV Infection in Children. Virologic, immunologic, and clinical benefits from early combined antiretroviral therapy in infants with perinatal HIV-1 infection. AIDS. 2006;20:207-215.4
14. Treluyer JM, Bowers G, Cazali N, et al. Oxidative metabolism of amprenavir in the human liver. Effect of the CYP3A maturation. Drug Metab Dispos. 2003;31:275-281.5
15. Faye A, Bertone C, Teglas JP, et al.; French Perinatal Study. Early multitherapy including a protease inhibitor for human immunodeficiency virus type 1-infected infants. Pediatr Infect Dis J. 2002;21:518-525.